Clinical trial
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
NCT00452218 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00452218 |
|---|---|
| Title | Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) |
| Official title | Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) |
| Lead sponsor | University of Chicago, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pulmonary Arterial Hypertension |
| Intervention type | Drug |
| Interventions | Sorafenib |
| Enrollment | 12 |
| Start date | Mar 1, 2007 |
| Primary completion | May 1, 2012 |
| Completion | May 1, 2012 |
| First posted | Mar 27, 2007 |
| Last update posted | Aug 24, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: